Form 4: Chimerix Executive Michael Alrutz Reports Stock and Option Awards

Chimerix SVP and General Counsel Michael Alrutz received stock awards and stock options, increasing his holdings in the company.

Summary

• Michael Alrutz, SVP and General Counsel at Chimerix, reported the acquisition of 41,667 shares of common stock through restricted stock units (RSUs) and 250,000 stock options on January 7, 2025.
• The RSUs vest over four years, with 10,416 shares vesting on the first anniversary, and 10,417 shares vesting on the second, third, and fourth anniversaries of the grant date.
• The stock options vest over 40 months, with one-fourth vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments.
• Mr. Alrutz also holds 215,196 shares of common stock, which includes shares acquired through the Employee Stock Purchase Plan (ESPP) on March 8, 2024 (2,429 shares) and September 10, 2024 (3,002 shares).

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align executive interests with shareholder value. There are no negative implications.

Positives

• The grant of RSUs and stock options to a key executive like Michael Alrutz can be seen as a positive incentive for his continued performance and alignment with shareholder interests.
• The vesting schedule of the RSUs and stock options encourages long-term commitment from the executive.

Risks

• The vesting of a large number of shares and options could potentially lead to dilution of existing shareholders' equity if exercised.

Industry Context

This type of stock and option grant is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded biotech companies like Chimerix.
• Companies such as Gilead Sciences, Amgen, and Biogen also use similar equity-based compensation to align executive interests with shareholder value.
• The vesting schedules of the RSUs and options are typical for the industry, designed to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Chimerix, stock options, restricted stock units, RSU, executive compensation, insider trading, stock ownership, Michael Alrutz, CMRX, ESPP